


## N3-PEG3-vc-PAB-MMAE

<b>Cat. No.:</b>	HY-100874
<b>Molecular Formula:</b>	C <sub>67</sub> H <sub>109</sub> N <sub>13</sub> O <sub>16</sub>
<b>Molecular Weight:</b>	1352.66
<b>Target:</b>	Drug-Linker Conjugates for ADC
<b>Pathway:</b>	Antibody-drug Conjugate/ADC Related
<b>Storage:</b>	Powder    -20°C    3 years 4°C        2 years



\* The compound is unstable in solutions, freshly prepared is recommended.

### BIOLOGICAL ACTIVITY

<b>Description</b>	N3-PEG3-vc-PAB-MMAE is a synthesized agent-linker conjugate for ADC that incorporates the MMAE (a tubulin inhibitor) and 3-unit PEG linker. N3-PEG3-vc-PAB-MMAE shows potent antitumor activity. N3-PEG3-vc-PAB-MMAE is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAC) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.
<b>IC<sub>50</sub> &amp; Target</b>	Auristatin
<b>In Vitro</b>	Monomethyl auristatin E (MMAE; SGD-1010) is a synthetic derivative of Dolastatin 10 and functions as a potent mitotic inhibitor by inhibiting tubulin polymerization. MMAE is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) to treat several different cancer types. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### CUSTOMER VALIDATION

- Angew Chem Int Ed Engl. 2020 Jul 27;59(31):12885-12893.
- Chembiochem. 2019 Sep 16;20(18):2411-2419.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA